Company Description
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression.
The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder.
Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.
ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
| Country | Germany |
| Founded | 2018 |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Florian Brand |
Contact Details
Address: Wallstrasse 16 Berlin, 2M 10179 Germany | |
| Phone | (617)-699-5876 |
| Website | atai.life |
Stock Details
| Ticker Symbol | ATAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001840904 |
| CUSIP Number | N0731H103 |
| ISIN Number | NL0015000DX5 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christian Angermayer | Founder and Chairman of the Supervisory Board |
| Florian Brand | Co-Founder and Chief Executive Officer |
| Dr. Srinivas G. Rao M.D., Ph.D. | Co-Founder and Chief Scientific Officer |
| Anne Johnson | Chief Financial Officer |
| Dr. Michael Raven Ph.D. | Senior Vice President of Operations |
| Frank Stegert | Vice President of Investment and Venture Management |
| Ryan Barrett | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Glenn Short Ph.D. | Senior Vice President of Early Development |
| Dr. Sahil V. Kirpekar M.D. | Chief Business Officer |
| Dr. Kevin Craig M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 8, 2024 | 144 | Filing |
| Apr 5, 2024 | 144 | Filing |
| Apr 4, 2024 | 144 | Filing |
| Apr 4, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |